ccfdna Webinar Series: The Basics and Beyond
|
|
- Hillary Bradley
- 6 years ago
- Views:
Transcription
1 ccfdna Webinar Series: The Basics and Beyond Part I Maxwell RSC ccfdna Plasma Kit and Maxwell RSC instrument are For Research Use Only. Not for Use in Diagnostic Procedures.
2 Introduction to Circulating, Cell-Free DNA Maxwell RSC ccfdna Plasma Kit and Maxwell RSC instrument are For Research Use Only. Not for Use in Diagnostic Procedures.
3 Nucleic Acids in Plasma mirna Exosomes Circulating, cell-free DNA (ccfdna) Circulation Research. 2012;110:
4 Micro RNA Small (~22nt) non-coding RNA that function in gene regulation There are thousands of sequences of mirna Surrounded by a large group of proteins Can exist in a stable form in plasma Found in most bodily fluids The presence and amount of certain mirna can serve as biomarkers for cancer 4
5 Exosomes First described in 1981 Microvesicles, nm, that are expelled by cells in a regulated process Contain protein, mrna, mirna and other noncoding RNA, and possibly DNA Have been shown to transport material between cells and organs Implicated in metastasis, cellular origin, immune regulation, blood coagulation, cell migration, cell differentiation Cellular and Molecular Life Sciences 2011; 68(16):
6 Exosomes in Metastasis Release of exosomes is a regulated process Destination of exosomes can lead to spread of cancer Seminars in Cancer Biology :
7 Circulating Cell-Free DNA A.K.A.: cfdna, ctdna, cfcdna Nucleosomal in size: ~170bp o Dimers and trimers can be seen Dilute: 5-30ng per ml plasma o Increases in cancer, trauma o Increased heart rate can increase levels Rapidly turned over o Half-life of 30 minutes o Allows snapshot of current genetic make up Memorial University, Faculty of Science - Biology BIOL2060/BIOL /18_21.jpg 7
8 ccfdna Timeline 8
9 Origins of ccfdna Secretion Cell releases DNA into bloodstream, remains alive Necrosis Caused by factors external to the cell o Infection, toxins, trauma Cell contents are released DNA degrades into nucleosomal units Apoptosis Programmed cell death Cell fragments into apoptotic bodies, which are digested by phagocytes Very little DNA released J Clin Oncol Feb 20; 32(6):
10 Other Forms of Cell-Free DNA Cell-free DNA has been detected in most biological fluids tested: o o o o o o Urine Cerebral-spinal fluid Pancreatic juice Saliva Sweat Tears Different fluids can be enriched with mutated DNA from associated organs 10
11 Differences in ccfdna from Different Sources Cell-free DNA from different sources exhibits different characteristics. Sizes of cell-free DNA from plasma and maternal urine Plasma Urine Blue: maternal Red: fetal PLoS One. 2012;7(10):e Maxwell RSC ccfdna Plasma Kit is For Research Use Only. Not for Use in Diagnostic Procedures. 11
12 Purification and Characterization of ccfdna
13 Collection of Blood from Patients 1 tube of blood typically contains: o ~10ml blood o ~4-5ml plasma 1 to 4 ml plasma is sufficient for many applications Increasing the amount of starting material increases final yield and concentration Availability of sample can be limiting 13
14 Blood Collection Tubes (BCTs) EDTA, Citrate, Heparin o Contain anticoagulant to prevent clotting o Stable at 4 C for up to a week o At room temperature, white blood cell lysis begins within a day Cell-Free DNA tubes o Contain a stabilizer to prevent white blood cell lysis o Stable at room temperature for 2 weeks Serum tubes o Allow clotting of proteins o White blood cells lyse LaboratoryInfo.com 14
15 Purification of ccfdna Blood is double spun (remove blood cells) ccfdna bound to matrix Wash Elute Automated/Manual purification 15
16 Quality of DNA by electrophoresis Automated electrophoresis method that allows determination of DNA size Can detect contaminating Genomic DNA Quantitation is +/- 25% Lane Starting Material 1 MW Markers 2 Plasma 3 Serum 4 Plasma + genomic DNA 16
17 Detection of ccfdna Levels of ccfdna are too low for A 260 determination dsdna specific fluorescent dyes are sensitive enough qpcr: sensitive ddpcr: sensitive, gives absolute quantitation Next-Generation Sequencing: determine genomic differences 17
18 Levels of ccfdna Cell-free DNA levels in plasma of patients with nonsmall-cell lung cancer and inflammatory lung disease Br J Cancer Jul 28; 113(3): Maxwell RSC ccfdna Plasma Kit is For Research Use Only. Not for Use in Diagnostic Procedures. 18
19 Increasing ccfdna Levels Through Exercise ccfdna Yield, Pre- and Post-Exercise Increased blood flow causes increased shedding of DNA into the bloodstream Blood was taken from an individual before and after 60 minutes of aerobic activity and analyzed by qpcr and BioAnalyzer Results showed a transient increase in ccfdna concentration 19
20 Serum vs. Plasma as Source Clotting allows lysis of WBCs, greatly increasing DNA yields with contaminating gdna BioAnalyzer Analysis In matched maternal samples, DNA purified from plasma and serum do not show an increase in fetal DNA levels DNA from Plasma and Serum, Same Donor Plasma Serum 20
21 Applications of ccfdna
22 pg/ul fetal DNA Both Maternal and Fetal ccfdna are Present in Pregnant Women Fetal ccfdna is present in maternal plasma Levels can increase to ~25% of total ccfdna Rapidly cleared after birth Detection of Fetal DNA in Maternal Plasma week of pregnancy sonicgenetics.com.au 22
23 Non-Invasive Prenatal Testing DNA is purified from the mother s plasma Fetal DNA is distinguished from maternal DNA o Paternal markers o Epigenetic markers Fetal DNA can be detected in the first weeks of pregnancy o Same size as maternal DNA own_rump_lengh_12_weeks_ecografia_dr._wolfgang_morod er.jpg Maxwell RSC ccfdna Plasma Kit is For Research Use Only. Not for Use in Diagnostic Procedures. 23
24 Fetal Applications of ccfdna Replacing amniocentesis o Detection of trisomy o Determine gender through Y chromosome detection o Detect marker for various X-linked conditions o Detection of Rh factor SNP Analysis o Paternity o Epigenetic fetal markers Maxwell RSC ccfdna Plasma Kit is For Research Use Only. Not for Use in Diagnostic Procedures. 24
25 ccfdna Use in Organ Transplants Heart transplants: 25-30% rejection in first year Endomyocardial biopsy (EMB) is the current gold standard. Removes a small piece of the myocardium. o EMB is widely used for surveillance of cardiac allograft rejection o Recipients receive multiple rounds of EMB 25
26 Using ccfdna as a Rejection Marker ccfdna can be used as a marker for rejection As donor ccfdna increases, rejection risk rises ccfdna is extracted from donor, purified, and sequenced Levels of donor DNA are determined Sci Transl Med Jun 18; 6(241): 241ra77. Maxwell RSC ccfdna Plasma Kit is For Research Use Only. Not for Use in Diagnostic Procedures. 26
27 Oncological Applications of ccfdna DNA from tumor cells is released into the blood where it is degraded Cancer patients frequently exhibit elevated levels of ccfdna First described in cancer patients in 1977 Recent advances in sequencing and PCR have made ccfdna a powerful oncological tool 27
28 Tumor Biomarkers in Plasma Microsatellite instability o Genetic hypermutability (predisposition to mutation) that results from impaired DNA mismatch repair (MMR) Epigenetic patterns o Changes in DNA and chromatin not related to DNA sequence. Mutations o KRAS o BRCA o SMD4 Maxwell RSC ccfdna Plasma Kit and Microsatellite Instability Analysis (MSI) are For Research Use Only. Not for Use in Diagnostic Procedures. 28
29 ccfdna and Microsatellite Instability Microsatellite: area of DNA repeats; 1-6 bp sequence repeats 5-50 times. MSI: genetic predisposition to mutation that results from impaired DNA mismatch repair (MMR). Certain MSIs are linked to certain cancers, especially colon. Representative capillary electrophoresis result for MSIHigh colorectal polyp 267B using long mononucleotides Bacher, et al. (2014). Potential new markers for detection of MSI in polyps and endometrial cancers. Maxwell RSC ccfdna Plasma Kit and Microsatellite Instability Analysis (MSI) are For Research Use Only. Not for Use in Diagnostic Procedures. 29
30 ccfdna and Epigenetics Epigenetics: All heritable changes in DNA/chromatin structure that are not coded in DNA itself o o o Methylation, and acetylation of both DNA and histones, RNA-mediated silencing. Methylation occurs on cytosine bases. Hyper- and hypo-methylation, and other modifications, leads to inappropriate gene expression. 30
31 Types of Tumor Biomarkers Prognostic Objectively evaluate the patient s overall outcome, such as the probability of cancer recurrence after standard treatment Useful for the selection of patients for treatment but does not directly predict the response to a treatment Predictive Determine the potential success rate of different types of treatment. Maxwell RSC ccfdna Plasma Kit is For Research Use Only. Not for Use in Diagnostic Procedures. 31
32 Detection of Mutations Percent of a sequence of DNA that is mutated usually correlates to the stage of the cancer. At early stages, mutation levels are 0.1%, increasing to >50% in later stages. Early detection of cancer requires sensitive detection levels. Mutations indicating a specific cancer are enriched in fluids associated with that organ: Urine: CSF: Pancreatic juice: Saliva: colon, kidney, prostate cancers brain cancer pancreatic cancer esophageal, stomach, oral cancers 32
33 Mutation Detection Levels qpcr, ddpcr and Next-Generation Sequencing (NGS) Comput Struct Biotechnol J Jun 1;14:
34 Amount of DNA Needed for Mutation Detection One copy (or genomic equivalent) = 3.3pg 1000 copies = 3 4pg 34
35 The Liquid Biopsy A less invasive biopsy than standard tissue biopsy Tissue Biopsy Liquid Biopsy Excised tissue Blood fixation Centrifuge for plasma Tumor embedding DNA Invasive Expensive Slow (time consuming) Tumor Safe Less expensive Rapid DNA 35
36 Additional Advantages of a Liquid Biopsy Heterogeneity of tumor cells o Early in progression it is very possible to miss cancerous tissue Homogeneity of plasma ccfdna Ability to detect secondary cancers by biomarkers Ease of sample collection Can take repeated samples sie_lunge_computertomographie_bc.png 36
37 Disadvantages of a Liquid Biopsy Heterogeneity in the amount of circulating DNA Uncertain source/location of cells producing the ccfdna Contaminating normal DNA may obscure detection of cancer/mutated ccfdna Somatic mutations are only detected in 70-80% of nonmetastatic cancers sie_lunge_computertomographie_bc.png 37
38 Repeated Sampling by Liquid Biopsy Enables Simple Assessment Over Time Ability to take repeated blood samples throughout treatment allows for: Earlier detection More samples from more patients Detection of actionable mutations Assessment of changes in mutation levels over time 38
39 Levels of Breast Cancer Mutations in a treated Patient As cancer is treated, general levels of ccfdna decrease If a relapse occurs, ccfdna levels can increase Once increased levels are detected, a different treatment can be pursued N Engl J Med Mar 28;368(13): Maxwell RSC ccfdna Plasma Kit is For Research Use Only. Not for Use in Diagnostic Procedures. 39
40 Liquid Biopsy and Precision Medicine Millions of tissue biopsies are performed yearly in the U.S. Liquid biopsies could provide an inexpensive way to screen for early detection of cancers As more data is generated, more biomarkers will be discovered NCI budget includes funds to monitor treatment over time using ccfdna accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select which treatments will work best for which patients. Many companies, both established and start-ups, are focusing on precision medicine and ccfdna to improve treatments of individual patients 40
41 Example of Precision Medicine Pembrolizumab (Keytruda) o humanized monoclonal antibody blocking the T-cell gene PD1 Patients with non-small cell lung cancer who do not have mutations in EGFR or ALK genes typically see positive effects when treated Efficacy of treatment is based on genetic markers 41
42 Summary ccfdna is dilute, highly fragmented, and a transient component of plasma ccfdna levels are increased by exercise, trauma, infection, or the presence of cancer Fetal ccfdna is a component of maternal plasma o Purification of ccfdna from maternal plasma allows analysis of fetal abnormalities such as trisomy Cancer biomarkers can be detected in ccfdna, allowing greatly improved treatment: o o o o Early detection Determination of cancer type Monitoring cancer levels Effectiveness of treatment Maxwell RSC ccfdna Plasma Kit is For Research Use Only. Not for Use in Diagnostic Procedures. 42
43 Coming soon ccfdna Webinar Series: The Basics and Beyond Part 2 ccfdna Workflows: Honing in on the Target Part 3 ccfdna In the Lab: Optimizing Purification for Sequencing Maxwell RSC ccfdna Plasma Kit and Maxwell RSC instrument are For Research Use Only. Not for Use in Diagnostic Procedures.
Products for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma
MACHEREY-NAGEL Products for cfdna and mirna isolation Bioanalysis Subhead Circulating Cover nucleic acids from plasma n Flexible solutions for small and large blood plasma volumes n Highly efficient recovery
More informationThor Nilsen NeoGeneStar LLC January 22, 2015
Thor Nilsen NeoGeneStar LLC January 22, 2015 NeoGeneStar TM I. Liquid biopsy using circulating cell-free DNA: Cancer diagnostics Prenatal diagnostics Other disease states II. NeoGeneStar TM cell-free DNA
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationConverting the Hype into Reality: Realizing the Potential of Cell-Free DNA
Converting the Hype into Reality: Realizing the Potential of Cell-Free DNA Lucy Xu, Ph.D. Associate Director Clinical Biomarker Research Eisai Inc. Woodcliff Lake, NJ Precision LBx Summit San Diego, CA
More informationQIAsymphony DSP Circulating DNA Kit
QIAsymphony DSP Circulating DNA Kit February 2017 Performance Characteristics 937556 Sample to Insight Contents Performance Characteristics... 4 Basic performance... 4 Run precision... 6 Equivalent performance
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationCirculating Cell-Free DNA Pre-analytics: Importance of ccfdna Stabilization and Extraction for Liquid Biopsy Applications
Circulating Cell-Free DNA Pre-analytics: Importance of ccfdna Stabilization and Extraction for Liquid Biopsy Applications Martin Schlumpberger, Ass.Director R&D, QIAGEN GmbH IQNpath 2017 - Circulating
More informationExosome DNA Extraction Kits
Exosome DNA Extraction Kits Summary Section 5 Introduction 40 EXO-DNAc 41 EXO-DNA 43 Introduction Genomic DNA Extractiom Kits Ordering informations Products can be purchased directly in our on-line shop:
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationA complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis
APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown
More informationIntroduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory
Introduction to liquid biopsies Rachel Butler All Wales Genetics Laboratory What is cell free DNA? Non-Invasive Prenatal Testing (NIPT) Extract DNA Genetic alterations detectable in circulating cell-free
More informationOverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA
OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.
More informationInsight into cancer research from discovery to validation
Insight into cancer research from discovery to validation 1 Exosomes in cancer research: from exosome isolation to biomarker discovery Zheng Songyue, PhD Technical Sales Specialists Life Technologies The
More informationThe use of diagnostic FFPE material in cancer epidemiology research
The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who
More informationDNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA
DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias
More informationYoungnam Cho. National Cancer Center Biomarker Branch
Youngnam Cho National Cancer Center Biomarker Branch Contents 1. Liquid Biopsy 2. Circulating Tumor Cells from Blood 3. Cell-free DNA from Blood 1. Liquid biopsy Cancer Diagnosis IMAGING TISSUE BIOPSY
More informationLukas Bubendorf Pathologie. Liquid biopsies
Lukas Bubendorf Pathologie Liquid biopsies Liquid biopsies 1. Circulating cell-free tumor-dna (ctdna) 2. Circulating tumor cells (CTC) Source: Sysmex CTCs ctdna ctrna exosomes Quantification Protein RNA
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationEXO-DNAc Circulating and EV-associated DNA extraction kit
Datasheet EXO-DNAc Circulating and EV-associated DNA extraction kit This product is for research use only. It is highly recommended to read this users guide in its entirety prior to using this product.
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationColon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP
Colon cancer: practical molecular diagnostics Wade S. Samowitz, M.D. University of Utah and ARUP Disclosure Dr. Samowitz may receive royalties in the future related to the Ventana BRAF V600E antibody.
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationQIAGEN's Growing Immuno-Oncology Testing Portfolio
QIAGEN's Growing Immuno-Oncology Testing Portfolio QIAGEN Your Partner in Translational Medicine Current Biomarkers of Immuno-Oncology Focus: Immuno-Oncology Testing Portfolio Tumor mutation burden (TMB)
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationFor Research Use Only Ver
INSTRUCTION MANUAL Quick-cfDNA Serum & Plasma Kit Catalog No. D4076 Highlights High-quality DNA, including cell-free, is easily and robustly purified from up to 10 ml of serum/plasma, up to 1 ml amniotic
More informationLynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017
1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand
More informationExtracellular Vesicle RNA isolation Kits
Extracellular Vesicle RNA isolation Kits Summary Section 4 Introduction 42 Exo-TotalRNA and TumorExo-TotalRNA isolation kits 43 Extracellular Vesicle RNA extraction kits Ordering information Products can
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationUniversal Screening for Lynch Syndrome
Universal Screening for Lynch Syndrome St. Vincent/Ameripath protocol proposal Lynch syndrome (HNPCC) 1/35 individuals with colorectal cancer has Lynch syndrome Over half individuals are >50 at time of
More informationvol.3 Highlight Product: ExoCap Product Research tools for extracellular vesicles - Exhibition booth at Taiwan on November
vol.3 Feb. 2018 Highlight Product: ExoCap Product Research tools for extracellular vesicles - Exhibition booth at Taiwan on November Exhibition / Webinar on March 2018 is a big year! CELEBRATE MBL 50th
More informationUrinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015
Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring Mark G. Erlander, Ph.D., CSO CHI Next Generation Summit August 19,2015 Circulating Tumor DNA (ctdna) Tumor cells Main Advantages of
More informationGPS Cancer. The Era of Complete Genomics and Proteomics is Here. Advanced molecular profiling to inform personalized treatment strategies
MOLECULAR PROFILING GPS Cancer The Era of Complete Genomics and Proteomics is Here Advanced molecular profiling to inform personalized treatment strategies www.nanthealth.com What information do you need
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationEnterprise Interest No
Enterprise Interest No SY-05 Pulmonary Pathology: Options for targeted therapy in lung cancer Liquid biopsy in thoracic oncology Where are we now? Paul Hofman Laboratory of Clinical and Experimental Pathology
More informationmicro-rnas as biomarkers in children who underwent surgery for CHD
micro-rnas as biomarkers in children who underwent surgery for CHD mentors: Dr. Yael Nevo-Caspi & Prof. Gidi Paret Or Bercovich Liat Mor What will we talk about Congenital heart defects (CHD) Scientific
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationMRC-Holland MLPA. Description version 29;
SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,
More informationEPIGENOMICS PROFILING SERVICES
EPIGENOMICS PROFILING SERVICES Chromatin analysis DNA methylation analysis RNA-seq analysis Diagenode helps you uncover the mysteries of epigenetics PAGE 3 Integrative epigenomics analysis DNA methylation
More informationEnterprise Interest Thermo Fisher Scientific / Employee
Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical
More informationShould novel molecular therapies replace old knowledge of clinical tumor biology?
Should novel molecular therapies replace old knowledge of clinical tumor biology? Danai Daliani, M.D. Director, 1 st Oncology Clinic Euroclinic of Athens Cancer Treatments Localized disease Surgery XRT
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationEXO-DNA Circulating and EV-associated DNA extraction kit
Datasheet EXO-DNA Circulating and EV-associated DNA extraction kit This product is for research use only. It is highly recommended to read this users guide in its entirety prior to using this product.
More information1000 Patient study of detection of CRC and polyps by serum ELISA of altered epigenetic signatures in circulating cell free nucleosomes
1000 Patient study of detection of CRC and polyps by serum ELISA of altered epigenetic signatures in circulating cell free nucleosomes 9 th International Conference of Anticancer Research Sithonia, Oct
More informationFor Research Use Only Ver
INSTRUCTION MANUAL Quick-cfDNA/cfRNA Serum & Plasma Kit Catalog No. R1072 Highlights High-quality cell-free DNA and RNA are easily and robustly purified from up to 3 ml of plasma, serum, or other biological
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationExpressArt FFPE Clear RNAready kit
Features and Example Results General problems with FFPE samples Formalin-fixation of tissues results in severe RNA fragmentation, as well as in RNA RNA, RNA-DNA and RNA protein cross-linking, which impairs
More informationUSE OF EXOSOMES IN TRANSLATIONAL AND CLINICAL RESEARCH. Eva Colás Ortega Postdoc researcher IRBLleida
USE OF EXOSOMES IN TRANSLATIONAL AND CLINICAL RESEARCH Eva Colás Ortega Postdoc researcher IRBLleida ecolas@irblleida.cat THERE ARE DIFFERENT TYPE OF VESICLES RELEASED BY CELLS MICROVESICLES Size: 100-1000nm
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationSALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407
SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407 The Mismatch Repair (MMR) system is critical for the maintenance of genomic stability. MMR increases the fidelity of DNA
More informationInformation Guide - August Liquid Biopsies for Cancer Management
Information Guide - August 2017 Liquid Biopsies for Cancer Management INFORMATION GUIDE - AUGUST 2017 Liquid Biopsies for Cancer Management CIRCULATING TUMOR DNA IN BLOOD AS A LIQUID BIOPSY FOR CANCER
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationRobert Beer
Robert Beer Robert.beer@wales.nhs.uk All Wales Medical Genetics Service Genetic Technologist Training Day 22 nd November 2017 Contents Stratified Medicine NHS EGFR Diagnostic Testing Services Cell free
More informationTargeted therapy & Tumor molecular profile. Anton Tikhonov V Bioinformatics Summer School, 2017
Targeted therapy & Tumor molecular profile Anton Tikhonov V Bioinformatics Summer School, 2017 What exactly is targeted therapy? It has target It was rationally designed Its target was discovered before
More informationConsensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018
Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018 Summary: This document follows on from the findings of the CM-Path The
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes The need for improved diagnostics At the advanced edge of oncology, rapid access to accurate data on disease state is vital. Current technologies such as
More informationPros and cons of liquid biopsy: Ready to replace tissue?
Pros and cons of liquid biopsy: Ready to replace tissue? 2-Day Molecular Biologists Symposium: Liquid biopsies Federico Rojo Enterprise Interest No disclosures. Biological limitations for molecular testing:
More informationEpigenetics: Basic Principals and role in health and disease
Epigenetics: Basic Principals and role in health and disease Cambridge Masterclass Workshop on Epigenetics in GI Health and Disease 3 rd September 2013 Matt Zilbauer Overview Basic principals of Epigenetics
More informationCollaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationCh. 18 Regulation of Gene Expression
Ch. 18 Regulation of Gene Expression 1 Human genome has around 23,688 genes (Scientific American 2/2006) Essential Questions: How is transcription regulated? How are genes expressed? 2 Bacteria regulate
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationA clear path forward COMING SOON THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
COMING SOON A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test which assesses organ
More informationIntroduction of Liquid Biopsy PROTEO
Introduction of Liquid Biopsy PROTEO Chapter 01 Super early cancer risk screening tests... 03 Chapter 02 PROTEO Approach for Problem-Solving... 04 Chapter 03 Solution for Transportation... 10 Chapter 04
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationFor purification of viral DNA and RNA from a wide range of sample materials
QIAamp virus kits For purification of viral DNA and RNA from a wide range of sample materials Automatable on QIAGEN s proven QIAamp Kits set the standard for purification of viral DNA and RNA. QIAamp virus
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationValidation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D
Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D Department of Radiation Oncology University of Florida College of Medicine Outline Objective
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationA clear path forward AVAILABLE NOW THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
AVAILABLE NOW A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test that assesses organ
More informationProduct Overview CELL-FREE DNA BCT CELL-FREE RNA BCT CELL-FREE DNA URINE PRESERVE CYTO-CHEX BCT STRECK CELL PRESERVATIVE
FIXED ON INTEGRITY Product Overview CELL-FREE DNA BCT A blood collection tube for stabilization of cell-free plasma DNA, CTCs and cellular DNA. The preservative in Cell-Free DNA BCT stabilizes nucleated
More informationProkaryotes and eukaryotes alter gene expression in response to their changing environment
Chapter 18 Prokaryotes and eukaryotes alter gene expression in response to their changing environment In multicellular eukaryotes, gene expression regulates development and is responsible for differences
More informationEXOSOMES & MICROVESICLES
The Sample Preparation Experts EXOSOMES & MICROVESICLES The New Standard in Exosome Purification and RNA Isolation Best-in-Class, Pure & Simple Exosome Purification, Fractionation of Exosomal Free & Circulating
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationBasket Trials: Features, Examples, and Challenges
: Features, s, and Challenges Lindsay A. Renfro, Ph.D. Associate Professor of Research Division of Biostatistics University of Southern California ASA Biopharm / Regulatory / Industry Statistics Workshop
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationApproval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology
Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Steven Lemery, MD, MHS Associate Director, DOP2 Traditional development paradigm Based on tumor
More informationWat is de potentiële waarde van ctdna? PLCRC - MEDOCC
Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC Translational Gastrointestinal Oncology Remond Fijneman r.fijneman@nki.nl Department of Pathology, Amsterdam, NL Wat is de potentiële waarde van ctdna?
More informationGenetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine
Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine Lynn Greenhalgh, Macmillan Cancer and General Clinical Geneticist Cancer Genetics Service Cancer is common 1 in
More informationChapter 40 Section 2 The Immune System
Chapter 40 Section 2 The Immune System Science Standard 10a What is the role of the skin in providing nonspecific defenses against infection? What is the function of the immune system? The immune system
More informationWhy Pathway Genomics. Advanced Genetic Testing Laboratory. General Health and Wellness. Liquid Biopsy. Hereditary Cancer.
Advanced Genetic Testing Laboratory General Health and Wellness Liquid Biopsy Hereditary Cancer Pharmacogenomics Carrier Screening Why Pathway Genomics Founded in 2008, Pathway Genomics offers digital
More informationCelvrij DNA: nieuwe diagnostische mogelijkheden
Celvrij DNA: nieuwe diagnostische mogelijkheden Dr. Helena Devos - Hematologie voor de huisarts 2.0 9 februari 2019 Content What is cell free DNA? Clinical applications: Prenatal: NIPT In oncology/hematology:
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationTranscriptional control in Eukaryotes: (chapter 13 pp276) Chromatin structure affects gene expression. Chromatin Array of nuc
Transcriptional control in Eukaryotes: (chapter 13 pp276) Chromatin structure affects gene expression Chromatin Array of nuc 1 Transcriptional control in Eukaryotes: Chromatin undergoes structural changes
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationCell-free DNA and Active Rejection in Kidney Allografts
Cell-free DNA and Active Rejection in Kidney Allografts Disclosures Jonathan S. Bromberg, MD, PhD Research Contract with CareDx, Inc. Statements in this presentation include the speaker s own opinions
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More information